ClinicalTrials.gg
CompletedNCT03364231Updated Jun 23, 2023Results posted

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

A Phase 2 interventional study of Umbralisib in Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia and Non Follicular Indolent Non-Hodgkin Lymphoma, sponsored by TG Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-23.

Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States — 57 open to participants now, 95 under way, 6 of them phase 3. Lymphoma, B-Cell, Marginal Zone · United States.

Enrollment
385th of 557
21 · median 36
Started
2017
with 24 others
Phase 2
224 of 674
20 open now
Registered
553rd of 674
by date

Among the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, this one is the 385th largest by enrollment of the 557 interventional ones that give a count, is one of 25 that started in 2017, is one of 224 in phase 2, and was the 553rd registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

57 of the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, or all of them as a file.
02

Study summary

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

03

Conditions studied

  • Marginal Zone Lymphoma
  • Waldenstrom Macroglobulinemia
  • Non Follicular Indolent Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Waldenstroms Macroglobulinemia
  • after at least one prior treatment regimen
  • (ECOG) score of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Evidence of virus, virus or known infection
  • Prior stem cell transplant within 6 months of study entry
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Marginal Zone Lymphoma (MZL): Umbralisib

    Participants with non-follicular indolent non-Hodgkin's lymphoma (iNHL) with MZL as the histology type received umbralisib, 800 milligrams (mg), orally, once daily (QD), until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.

    Drug: Umbralisib

  • Experimental
    Waldenstrom's Macroglobulinemia (WM): Umbralisib

    Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.

    Drug: Umbralisib

Interventions

  • Oral Daily Dose

    Also known as: TGR-1202

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)

    ORR for MZL=percentage of participants with complete response (CR)/partial response (PR). ORR for WM=CR/PR/very good partial response (VGPR)/minor response (MR). Response assessed per revised Lugano Classification for MZL \&per IWWM for WM participants. Per Lugano criteria CR=complete disappearance of all evidence of disease \& disease-related symptoms. PR=regression of measurable disease \& no new disease sites. Regression=≥50% decrease in the sum of the products of the diameters (SPD) of index lesions, with no increase in size of other lymph nodes/liver/spleen.Per IWWM criteria CR=disappearance of serum monoclonal immunoglobulin M (IgM) protein by immunofixation with a normal serum IgM level. VGPR=reduction of monoclonal IgM protein \>90% from baseline. PR=reduction of monoclonal IgM protein between 50-90% from baseline with regression of measurable disease. Regression defined in similar manner as Lugano Classification. MR=reduction of monoclonal IgM protein \>25% but \<50% from baseline.

    Time frame: Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years

  2. Duration of Response (DOR)

    DOR is defined as the time from documentation of a response to treatment to the first documentation of tumor progression or death due to any cause, whichever comes first.

    Time frame: From the first demonstration of response to umbralisib till disease progression/death (up to approximately 4.2 years)

Secondary outcomes

  1. Complete Response (CR) Rate

    CR rate is defined as percentage of participants who achieved CR. CR was assessed using Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) for participants with MZL and Consensus-Based 6th IWWM for participants with WM. Per Lugano Classification, CR= the complete disappearance of all evidence of disease and disease-related symptoms i.e., liver/spleen non palpable and normal in size and disappearance of nodules related to lymphoma. Per IWWM criteria, CR=disappearance of serum monoclonal IgM protein by immunofixation with a normal serum IgM level, liver/spleen non palpable and normal in size and disappearance of nodes related to WM.

    Time frame: Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years

  2. Progression-Free Survival (PFS)

    PFS is defined as the interval from Cycle 1 (1 cycle = 28 days) Day 1 to the earlier of the first documentation of definitive disease progression or death from any cause. Assessment of progressive disease (PD) was based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 centimeters (cm) in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, greatest transverse diameter (GTD) of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria participants, PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

    Time frame: From date of randomization until the date of first documented progression (up to approximately 4.2 years)

  3. Time to Treatment Failure (TTF)

    TTF is defined as a composite endpoint measuring time from Cycle 1/Day 1 to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death. PD was assessed based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 cm in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, GTD of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

    Time frame: From first dose on Day 1 of Cycle 1 (28 days = 1 cycle) up to discontinuation of treatment (up to approximately 4.2 years)

  4. Number of Participants With at Least One Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant that does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From first dose of study treatment up to end of study (up to approximately 4.2 years)

07

Results

Posted Jun 23, 2023

Participant flow

A total of 21 participants were enrolled at 4 investigative centers across the United States from 30 November 2017 to 15 February 2022.

Participant flow — Overall Study
MilestoneMarginal Zone Lymphoma (MZL): UmbralisibWaldenstrom's Macroglobulinemia (WM): Umbralisib
Started813
Safety population813
Modified intent-to-treat (mitt)810
Completed00
Not completed813
Withdrew: Adverse event14
Withdrew: Death10
Withdrew: Investigator decision22
Withdrew: Sponsor discontinuation of the study21
Withdrew: Withdrawal of subject consent10
Withdrew: Reason not specified10
Withdrew: Disease progression06

Outcome measures

PrimaryOverall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)

ORR for MZL=percentage of participants with complete response (CR)/partial response (PR). ORR for WM=CR/PR/very good partial response (VGPR)/minor response (MR). Response assessed per revised Lugano Classification for MZL \&per IWWM for WM participants. Per Lugano criteria CR=complete disappearance of all evidence of disease \& disease-related symptoms. PR=regression of measurable disease \& no new disease sites. Regression=≥50% decrease in the sum of the products of the diameters (SPD) of index lesions, with no increase in size of other lymph nodes/liver/spleen.Per IWWM criteria CR=disappearance of serum monoclonal immunoglobulin M (IgM) protein by immunofixation with a normal serum IgM level. VGPR=reduction of monoclonal IgM protein \>90% from baseline. PR=reduction of monoclonal IgM protein between 50-90% from baseline with regression of measurable disease. Regression defined in similar manner as Lugano Classification. MR=reduction of monoclonal IgM protein \>25% but \<50% from baseline.

Time frame:
Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
percentage of participantsMZL: UmbralisibWM: Umbralisib
Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)37.5 (8.5 to 75.5)30.0 (6.7 to 65.2)
PrimaryDuration of Response (DOR)

DOR is defined as the time from documentation of a response to treatment to the first documentation of tumor progression or death due to any cause, whichever comes first.

Time frame:
From the first demonstration of response to umbralisib till disease progression/death (up to approximately 4.2 years)
Reported as:
Median · months
Duration of Response (DOR)
monthsMZL: UmbralisibWM: Umbralisib
Duration of Response (DOR)21.2 (3 to 33)13 (5 to 14)
SecondaryComplete Response (CR) Rate

CR rate is defined as percentage of participants who achieved CR. CR was assessed using Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) for participants with MZL and Consensus-Based 6th IWWM for participants with WM. Per Lugano Classification, CR= the complete disappearance of all evidence of disease and disease-related symptoms i.e., liver/spleen non palpable and normal in size and disappearance of nodules related to lymphoma. Per IWWM criteria, CR=disappearance of serum monoclonal IgM protein by immunofixation with a normal serum IgM level, liver/spleen non palpable and normal in size and disappearance of nodes related to WM.

Time frame:
Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsMZL: UmbralisibWM: Umbralisib
Complete Response (CR) Rate12.5 (0.3 to 52.7)0 (NA to NA)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the interval from Cycle 1 (1 cycle = 28 days) Day 1 to the earlier of the first documentation of definitive disease progression or death from any cause. Assessment of progressive disease (PD) was based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 centimeters (cm) in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, greatest transverse diameter (GTD) of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria participants, PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

Time frame:
From date of randomization until the date of first documented progression (up to approximately 4.2 years)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsMZL: UmbralisibWM: Umbralisib
Progression-Free Survival (PFS)47.1 (1.4 to 47.1)18.4 (2.1 to 35.0)
SecondaryTime to Treatment Failure (TTF)

TTF is defined as a composite endpoint measuring time from Cycle 1/Day 1 to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death. PD was assessed based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 cm in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, GTD of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.

Time frame:
From first dose on Day 1 of Cycle 1 (28 days = 1 cycle) up to discontinuation of treatment (up to approximately 4.2 years)
Reported as:
Median · months
Time to Treatment Failure (TTF)
monthsMZL: UmbralisibWM: Umbralisib
Time to Treatment Failure (TTF)13.1 (1.4 to NA)6.5 (2.1 to 15.9)
SecondaryNumber of Participants With at Least One Adverse Event (AE)

An AE is any untoward medical occurrence in a participant that does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
From first dose of study treatment up to end of study (up to approximately 4.2 years)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event (AE)
ParticipantsMZL: UmbralisibWM: Umbralisib
Number of Participants With at Least One Adverse Event (AE)813

Adverse events

Collected over From first dose of study treatment up to end of study (up to approximately 4.2 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MZL: Umbralisib1/8 (12.5%)1/8 (12.5%)8/8 (100%)
WM: Umbralisib0/13 (0%)0/13 (0%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventMZL: UmbralisibWM: Umbralisib
ColitisGastrointestinal disorders1/80/13
Most frequent other events
Showing 10 of 109
Most frequent other events
EventMZL: UmbralisibWM: Umbralisib
DiarrhoeaGastrointestinal disorders4/810/13
NauseaGastrointestinal disorders4/87/13
CoughRespiratory, thoracic and mediastinal disorders1/85/13
DizzinessNervous system disorders3/84/13
AnaemiaBlood and lymphatic system disorders2/84/13
Alanine aminotransferase increasedInvestigations2/84/13
Aspartate aminotransferase increasedInvestigations2/84/13
Abdominal distensionGastrointestinal disorders2/83/13
Abdominal painGastrointestinal disorders2/81/13
FatigueGeneral disorders2/83/13

Baseline characteristics

Safety population included all enrolled participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)MZL: UmbralisibWM: UmbralisibTotal
Mean71.9 ± 7.6467.7 ± 5.7869.3 ± 6.69
Sex: Female, Male
Sex: Female, Male(Participants)MZL: UmbralisibWM: UmbralisibTotal
Female4610
Male4711
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MZL: UmbralisibWM: UmbralisibTotal
White61117
Black or African American112
Asian101
Other011
08

Study locations

4 sites
  • TG Therapeutics Investigational Trial Site
    Washington, District of Columbia 20007, United States
  • TG Therapeutics Investigational Trial Site
    Boston, Massachusetts 02215, United States
  • TG Therapeutics Investigational Trial Site
    Hackensack, New Jersey 07601, United States
  • TG Therapeutics Investigational Trial Site
    New York, New York 10065, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Feb 2022, 50 months.

Results were first posted in Jun 2023, 1 year 4 months after primary completion.

Of 113 phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 50 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 6, 2017
StartActual
Nov 30, 2017
Primary completionActual
Feb 15, 2022
CompletionActual
Feb 15, 2022
Results first posted
Jun 23, 2023
Last update
Jun 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03364231
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Nov 30, 2017
Primary completion
Feb 15, 2022
Completion
Feb 15, 2022
Results posted
Jun 23, 2023
Last update
Jun 23, 2023

Study contacts

Bruce Cheson, MD
study chair · Lombardi Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Umbralisib

Start the discussion